glp-1 obesity drug news today october 16 2025 What's next for innovation: A primer on the race reshaping pharma and chronic disease care The GLP-1 Revolution Continues
Description
Glucagon-like peptide 1 (GLP-1) receptor agonist: The gastrointestinal tract releases GLP-1, a major incretin, in response to glucose consumption

[DOI] [PubMed] [Google Scholar] Aspnes G

They can also watch for rarer, more dangerous risks, such as gallbladder inflammation, gallstones, and pancreatitis

Merck's Metabolic Disease Portfolio Mercks collaboration with Hansoh Pharma will enhance its portfolio in the growing areas of diabetes and obesity management

Mechanism: This effect is mediated by the activation of the vagus nerve and direct effects on gastric smooth muscle (Zheng et al., 2024)

A separate Medicare GLP1 payment demonstration begins July 2026, under which eligible beneficiaries pay $50 per month for GLP1 medications